(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally...
Stats | |
---|---|
今日成交量 | 91 480.00 |
平均成交量 | 74 840.00 |
市值 | 4 517.47B |
EPS | KRW0 ( 2024-03-15 ) |
下一个收益日期 | ( KRW-238.82 ) 2024-05-09 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW114.36 (0.19%) |
音量 相关性
SK bioscience Co.,Ltd. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
SK bioscience Co.,Ltd. 相关性 - 货币/商品
SK bioscience Co.,Ltd. 财务报表
Annual | 2023 |
营收: | KRW369.51B |
毛利润: | KRW136.40B (36.92 %) |
EPS: | KRW290.65 |
FY | 2023 |
营收: | KRW369.51B |
毛利润: | KRW136.40B (36.92 %) |
EPS: | KRW290.65 |
FY | 2022 |
营收: | KRW456.73B |
毛利润: | KRW239.61B (52.46 %) |
EPS: | KRW1 596.18 |
FY | 2021 |
营收: | KRW929.00B |
毛利润: | KRW570.28B (61.39 %) |
EPS: | KRW5 798.46 |
Financial Reports:
No articles found.
SK bioscience Co.,Ltd.
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。